Welcome to the Pennsylvania Rheumatology Society
The Pennsylvania Rheumatology Society (PRS) was established in 1987 to advance the knowledge of rheumatology and to foster the dissemination of this knowledge through educational endeavors and cooperation with other local and national societies of Rheumatology. PRS has been working for more than thirty years to support the interests of rheumatologists and their patients in the state by keeping our members up to date on legislative issues impacting rheumatology, and encouraging timely member outreach on local, state and federal levels. PRS provides significant funding support for training and education of Fellows. And for all, PRS provides CME opportunities, both in-person and virtual, relevant to the latest research in rheumatology. |
2024 ASM Exhibitor and Sponsor Registration now open! Exhibitors and Sponsors
|
|
To register for Dr. Buyon's lecture: Cross Border Lecture July 23 To register for Dr. Calabrese's lecture: Cross Border Lecture August 7 |
Earn up to 1.00 AMA PRA Category 1 Credit(s)™ when you join us for Dr. Buyon's talk!
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Pennsylvania Medical Society and the Pennsylvania Rheumatology Society. The Pennsylvania Medical Society is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
The Pennsylvania Medical Society designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Pennsylvania Medical Society and the Pennsylvania Rheumatology Society. The Pennsylvania Medical Society is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
The Pennsylvania Medical Society designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
On behalf of our collegue, Rohit Aggarwal:
Dear Pennsylvania Society of Rheumatology,
As a professor of medicine, in the Division of Rheumatology and Clinical Immunology at the University of Pittsburgh, I am writing to seek your invaluable support in disseminating crucial information regarding an innovative decentralized clinical trial focused on myositis-ILD to the esteemed rheumatology members of Florida Society of Rheumatology.
This pioneering clinical trial involves the use of Nintedanib in the treatment of Myositis-ILD (MINT study), providing patients with the opportunity to participate in the trial from the comfort of their own homes, regardless of their geographical location within the United States. Local rheumatologists and pulmonologists will serve as essential physician partners in this trial.
The burden imposed upon local rheumatologists and pulmonologists in this trial is minimal, limited solely to the referral of patients and the provision of necessary medical records. No additional regulatory obligations, such as IRB approval, are required.
For further information see clinicaltrial.gov: bit.ly/MINTstudy
Rohit Aggarwal MD MS
Medical Director, Arthritis and Autoimmunity Center
Professor of Medicine
Co-director, UPMC Myositis Center
Division of Rheumatology and Clinical Immunology
University of Pittsburgh
Dear Pennsylvania Society of Rheumatology,
As a professor of medicine, in the Division of Rheumatology and Clinical Immunology at the University of Pittsburgh, I am writing to seek your invaluable support in disseminating crucial information regarding an innovative decentralized clinical trial focused on myositis-ILD to the esteemed rheumatology members of Florida Society of Rheumatology.
This pioneering clinical trial involves the use of Nintedanib in the treatment of Myositis-ILD (MINT study), providing patients with the opportunity to participate in the trial from the comfort of their own homes, regardless of their geographical location within the United States. Local rheumatologists and pulmonologists will serve as essential physician partners in this trial.
The burden imposed upon local rheumatologists and pulmonologists in this trial is minimal, limited solely to the referral of patients and the provision of necessary medical records. No additional regulatory obligations, such as IRB approval, are required.
For further information see clinicaltrial.gov: bit.ly/MINTstudy
Rohit Aggarwal MD MS
Medical Director, Arthritis and Autoimmunity Center
Professor of Medicine
Co-director, UPMC Myositis Center
Division of Rheumatology and Clinical Immunology
University of Pittsburgh
PRS 2024 Membership Dues Renewal
Have you received your Membership Renewal email? Pay your dues here: https://prs.joynportal.com/member-login/
New News! Read the June 2024 PRS Connect!
Scenes from the PRS 2023 Annual Scientific Meeting